Search…
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Search...
TOP News
Latest
Recommend
HK Stock
US Stock
China Stock
Macro
Bond
Commercial
Global
Investment&Financing
Company&Products
Character
ESG
Economy&politics
Hong Kong
China
America
Stocks
HK Stock
China Stock
US Stock
Markets
HK Stock
US Stock
IPO
Hong Kong
America
China
Research
US Stock
HK Stock
Opinion
Recommendation
Home
>
Latest
Lates News
19/09/2025
Federal Reserve's Kashkari: the upcoming interest rate cut is a kind of insurance to maintain stability in the job market.
Latest
2 m ago
Qidi New Materials: Received designated and small batch orders for carbon fiber shells of humanoid robots from a leading domestic host factory.
2 m ago
Spot silver rose by 1.5% intraday, reaching $42.42 per ounce.
2 m ago
US stocks surge | Pony.ai (PONY.US) increases by over 4%, CFO says key profitability goal will be achieved in early 2026
3 m ago
WTI crude oil futures fell by 0.4% to $62.60. The Japanese ETF listed in the US fell by 0.77% to $80.86, dropping by over 1.1% at the start of trading.
3 m ago
In early trading on Friday, the Dow component Johnson & Johnson rose 1%. Recently, Johnson & Johnson announced that it has submitted an application to the European Medicines Agency seeking approval for the marketing of Icotrokinra, an investigational once-daily oral peptide therapy developed in collaboration with Protagonist. It is intended for the treatment of adults and pediatric patients aged 12 and above with moderate to severe plaque psoriasis. The experimental psoriasis drug is said to show potential superiority over AbbVie's therapy.
See all latest